NAPSR News: Pfizer will acquire Hospira for $17 billion

By:
 
WASHINGTON - Feb. 5, 2015 - PRLog -- Pfizer Inc has announced their plans to acquire Hospira, Inc in a deal worth approximately $17 billion dollars. Hospira is the world’s leading provider in injectable drugs, infusion technologies and biosimilars. "The proposed acquisition of Hospira demonstrates our commitment to prudently deploy capital to create shareholder value and deliver incremental revenue and EPS growth in the near-term," said Ian Read, Chairman and Chief Executive Officer, Pfizer. "In addition, Hospira’s business aligns well with our new commercial structure and is an excellent strategic fit for our Global Established Pharmaceutical business, which will benefit from a significantly enhanced product portfolio in growing markets. Coupled with Pfizer’s global reach, Hospira is expected to drive greater sustainability for our Global Established Pharmaceutical business."

Pfizer anticipates its GEP business unit will experience positive momentum in revenue growth from the expanded portfolio which includes Hospira’s sterile injectable pharmaceuticals, acute care and oncology injectables, biosimilars portfolio, and  anti-infectives, anti-inflammatories and cytotoxics. Pfizer will continue to drive the promotion of the Hospital’s products by utilizing its existing commercial proficiencies in key emerging markets including the United States and Europe.  John Young, group president, Pfizer Global Established Pharmaceutical business stated, "We're excited to combine Hospira’s expertise and key talent with that of Pfizer to create a leading global business that will deliver an even broader portfolio of important and life-saving sterile injectable medicines to patients around the world."

The transaction is subject to customary closing conditions and is expected to close in the second half of 2015.

ABOUT US

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/ (http://napsronline.org/)

Contact
NAPSRx
***@napsronline.org
1-800-284-1060
End
NAPSRx PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share